Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Lake Street Advisors Group LLC

Lake Street Advisors Group LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,774 shares of the biopharmaceutical company’s stock after acquiring an additional 473 shares during the quarter. Lake Street Advisors Group LLC’s holdings in Gilead Sciences were worth $1,490,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of GILD. Ballentine Partners LLC raised its stake in Gilead Sciences by 73.9% in the 3rd quarter. Ballentine Partners LLC now owns 19,880 shares of the biopharmaceutical company’s stock worth $1,667,000 after acquiring an additional 8,451 shares during the last quarter. Tectonic Advisors LLC increased its holdings in shares of Gilead Sciences by 15.1% in the third quarter. Tectonic Advisors LLC now owns 75,706 shares of the biopharmaceutical company’s stock valued at $6,347,000 after purchasing an additional 9,958 shares during the period. Cambridge Advisors Inc. purchased a new position in shares of Gilead Sciences in the third quarter worth about $222,000. Assenagon Asset Management S.A. boosted its position in Gilead Sciences by 159.8% in the third quarter. Assenagon Asset Management S.A. now owns 2,337,717 shares of the biopharmaceutical company’s stock valued at $195,994,000 after buying an additional 1,437,842 shares during the last quarter. Finally, Cherry Creek Investment Advisors Inc. increased its holdings in Gilead Sciences by 6.4% in the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 5,260 shares of the biopharmaceutical company’s stock worth $441,000 after buying an additional 317 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $95.00 price target on shares of Gilead Sciences in a research report on Wednesday, September 11th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $70.00 price target on shares of Gilead Sciences in a research report on Monday, September 16th. Sanford C. Bernstein assumed coverage on Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target on the stock. Raymond James raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target on the stock in a research report on Monday, July 8th. Finally, Barclays increased their price target on Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Ten research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.85.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 36,847 shares of company stock valued at $3,033,340 over the last quarter. 0.16% of the stock is owned by insiders.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $89.00 on Friday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $89.74. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The stock has a market cap of $110.88 billion, a PE ratio of 247.22, a P/E/G ratio of 2.98 and a beta of 0.18. The stock has a 50 day moving average price of $82.16 and a 200 day moving average price of $73.28.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. The company had revenue of $6.95 billion during the quarter, compared to analysts’ expectations of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Equities research analysts expect that Gilead Sciences, Inc. will post 3.78 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, September 13th. This represents a $3.08 annualized dividend and a yield of 3.46%. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.